IG4 Capital Acquires 50% Stake in Braskem From Novonor for $3.7B

Why It Matters

Braskem's privatization could accelerate restructuring and capital deployment in Latin America’s petrochemical sector, while Lilly's purchase strengthens its pipeline in the competitive blood‑cancer market, potentially reshaping treatment standards.

Key Takeaways

• IG4 acquires 50.1% of Braskem for roughly $3.7 billion.
• Braskem's 2025 sales hit $12.7 billion, boosting its valuation.
• Lilly pays $2.3 billion for Ajax's JAK2 blood‑cancer drug.
• Private‑equity entry signals consolidation trend in Latin American chemicals.
• Ajax's AJ1‑11095 in Phase 1 offers alternative to resistant JAK inhibitors.

Pulse Analysis

The IG4 Capital acquisition of Braskem marks one of the largest private‑equity forays into Latin America’s petrochemical arena. By taking control of more than half of the company’s common shares, IG4 gains a platform that benefits from Braskem’s low‑cost U.S., Canadian and Argentine assets, which have become increasingly valuable as Middle‑East supply disruptions lift global ethylene and polyethylene prices. The infusion of private‑equity capital is expected to fund modernization projects, improve debt structures, and potentially accelerate Braskem’s expansion into higher‑margin specialty chemicals, positioning it to capture a larger share of the post‑conflict market rebound.

Eli Lilly’s $2.3 billion bid for Ajax Therapeutics reflects a strategic push into the blood‑cancer segment, where unmet needs remain despite existing JAK2 inhibitors. Ajax’s lead candidate, AJ1‑11095, is a type II JAK2 inhibitor designed to overcome resistance mechanisms that limit the efficacy of first‑generation type I drugs. By integrating this pipeline, Lilly not only diversifies its oncology portfolio but also strengthens its foothold in myeloproliferative neoplasms, a market projected to grow as diagnostic capabilities improve. The deal also illustrates how large pharma firms are leveraging acquisitions to supplement internal R&D pipelines and shorten time‑to‑market for innovative therapies.

Together, these transactions highlight a broader trend of consolidation across both chemicals and biopharma as firms seek scale, technology access, and resilience against geopolitical volatility. Private‑equity investors are attracted to the cash‑generating potential of petrochemical assets that can exploit price differentials, while pharmaceutical giants are pursuing niche biotech targets to sustain growth amid slowing organic pipelines. Analysts anticipate that the capital allocated in these deals will spur further investment in advanced manufacturing, carbon‑capture technologies, and precision medicine, reshaping competitive dynamics over the next decade.

Deal Summary

Brazilian private‑equity firm IG4 Capital agreed to purchase Novonor’s 50.1% stake in Braskem, the country’s largest chemical maker, for roughly $3.7 billion. The transaction gives IG4 control of Braskem’s common shares and debt, while Novonor retains a 4% stake. The deal was announced on April 28 2026.